2nd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$680,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 3 - Lower Drug Costs Now Act; Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs H.R. 2846 - Ensuring Access to Lower-Cost Medicines for Seniors Act; Generic drug quality and FDA oversight H.R. 5376 - Build Back Better Act; Part D Formulary Design and Generic Drug Tiering S. 4348 - the Food and Drug Administration Safety and Landmark Advancements Act of 2022 Biosimilar interchangeability Part D Formulary Design and Generic Drug Tiering; Electronic labeling of prescription drugs H.R. 7667 - the Food and Drug Amendments of 2022; H.R. 8239 - Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2023, and for other purposes. FDA facility inspections Medicate incentives for biosimilar utilization Complex Generic Drug Approvals

LobbyistCovered position, as disclosed
WILL DENT —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 8239 (117th), H.R. 7667 (117th), H.R. 3 (117th), H.R. 2846 (117th), S. 4348 (117th), H.R. 5376 (117th)

Budget/Appropriations BUD

Medicaid Rebate provision of the Bipartisan Budget Act of 2015

LobbyistCovered position, as disclosed
WILL DENT —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs Patent Settlements S4417 - Patent Trial and Appeal Board (PTAB) Reform Act of 2022

LobbyistCovered position, as disclosed
WILL DENT —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

Trade issues related to generic medicines Pharmaceutical supply chain

LobbyistCovered position, as disclosed
WILL DENT —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE

Financial Institutions/Investments/Securities FIN

Policy related to corporate governance

LobbyistCovered position, as disclosed
DAVID MARIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Corporate Tax Policy

LobbyistCovered position, as disclosed
WILL DENT —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.